Take a trial of UK to unlock this pageFind out more


AZN 5122p 64.0  1.3%
28/09/16 0.500k

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 2 / 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2010 2011 2012 2013 2014 2015 TTM 2016E 2017E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 11th Aug, paid: 12th Sep more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ -2.4%

FINANCIAL BRIEF: For the six months ended 30 June 2016, AstraZeneca plc revenues decreased 5% to $11.72B. Net income decreased 48% to $643M. Revenues reflect United States segment decrease of 7% to $4.21B, Western Europe segment decrease of 5% to $2.47B. Net income also reflects Other Operating Income/Expenses decrease of 34% to $468M (income), Research and development expense - Balan increase of 7% to $2.81B (expense). Dividend per share remained flat at $0.90. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Jun '16) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2016
31st Dec 2017

Price Target: $66.7
(+1.61% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +5.3% ($) (¢) (¢) ($) (¢) (¢)
Consensus Estimate
1m Change
3m Change
32 brokers Broker Consensus Trend
Broker Recommendations for AstraZeneca
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 3 12 8 6

Named Brokers and Analysts
Jefferies Jeffrey Holford , Credit Suisse Matthew Weston , Piper Jaffray Richard Purkiss , SEB Equities , Leerink Partners LLC Seamus Fernandez , BERNSTEIN Tim Anderson , Danske Markets Lars Hevreng , Panmure Gordon , Natixis Jean-Jacques Le Fur , Mirabaud Securities Nicholas Turner , Swedbank Markets Johan Unnerus , Nordea Markets Michael Novod , Societe Generale Justin Smith , Pareto Securities AS Finlay Heppenstall , Berenberg Alistair Campbell , Oddo Securities Pierre Corby , Helvea SA Odile Rundquist , Shore Capital Stockbrokers Tara Raveendran , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Liberum Naresh Chouhan , Cantor Fitzgerald Europe Brian White , Baader Helvea Equity Research Odile Rundquist ,

Profile Summary

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Directors: Pascal Soriot (CEO) 56, Marc Dunoyer (CFO) 62, Fiona Cicconi (EVP) , Sean Bohen (EVP) , Ruud Dobber (EVP) , Paul Hudson (EVP) , Bahija Jallal (EVP) , Mark Mallon (EVP) , Luke Miels (EVP) , Menelas Pangalos (EVP) , Leif Johansson (NEC) 65, Cornelia Bargmann (NED) , Genevieve Berger (NED) 61, Ann Cairns (NED) 59, Tim Jackson-Smith (NED) ,

No. of Employees: 61,500 No. of Shareholders: 97,260

Last Annual December 31st, 2015
Last Interim June 30th, 2016
Incorporated June 17, 1992
Public Since September 21, 2007
Shares in Issue 1,264,983,797
Free Float 1.26bn (99.7%)

Address - Legal Department 2 Kingdom Street, LONDON, W2 6BD, United Kingdom
Web http://www.astrazeneca.com/
Phone +44 20 73045000
Contact Thomas Larsen (IR Contact Officer)
Auditors KPMG LLP

AZN Share Price Performance AZNQuote
64.0  1.3%
Traded 4:35pm · Minimum 15 min delayed · NMS: 0.500k

Latest AZN News Announcements (delayed)

Upcoming AZN Events
Thursday 29th September, 2016
AstraZeneca PLC at Leerink Partners Rare Disease & IO Roundtable Series
Thursday 10th November, 2016
Q3 2016 AstraZeneca PLC Earnings Release

Recent ↓
Thursday 22nd September, 2016
AstraZeneca PLC Investor Roadshow - Helsinki & Oslo
Thursday 22nd September, 2016
AstraZeneca PLC Investor Roadshow - Dublin
Wednesday 21st September, 2016
AstraZeneca PLC at Mizuho Neuro-Focus Therapeutics Conference
Wednesday 14th September, 2016
AstraZeneca PLC at Bank of America Merrill Lynch Healthcare Conference
Tuesday 13th September, 2016
AstraZeneca PLC Investor Roadshow - Copenhagen
Monday 12th September, 2016
AstraZeneca PLC at Morgan Stanley Global Healthcare Conference
Thursday 8th September, 2016
AstraZeneca PLC Investor Roadshow - Benelux
Wednesday 7th September, 2016
AstraZeneca PLC at Wells Fargo Securities Healthcare Conference
Wednesday 7th September, 2016
AstraZeneca PLC Investor Science Conference Call at the European Society International Congress
Wednesday 24th August, 2016
AstraZeneca PLC Investor Roadshow - Mid West
Wednesday 24th August, 2016
AstraZeneca PLC at CFA Society of Minnesota's InvestMNt Conference
Thursday 11th August, 2016
Dividend For AZN.L
Wednesday 10th August, 2016
Dividend For AZN
Wednesday 10th August, 2016
Dividend For AZN.BA
Monday 1st August, 2016
AstraZeneca PLC Investor Roadshow - London, Edinburgh, Europe and North America
Thursday 28th July, 2016
Q2 2016 AstraZeneca PLC Earnings Call
Thursday 28th July, 2016
Q2 2016 AstraZeneca PLC Earnings Release
Wednesday 6th July, 2016
AstraZeneca PLC IR Roadshow - Munich
Tuesday 5th July, 2016
AstraZeneca PLC IR Roadshow - Cologne, Stuttgart
Tuesday 21st June, 2016
AstraZeneca PLC at Citi European Healthcare Conference

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.

Should you buy AZN

Access AZN Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis